Key Insights on Gross Profit: AbbVie Inc. vs Dr. Reddy's Laboratories Limited

Pharma Giants' Profit Battle: AbbVie vs Dr. Reddy's

__timestampAbbVie Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 20141553400000075801000000
Thursday, January 1, 20151835900000085403000000
Friday, January 1, 20161980500000092281000000
Sunday, January 1, 20172117600000078356000000
Monday, January 1, 20182503500000076304000000
Tuesday, January 1, 20192582700000083430000000
Wednesday, January 1, 20203041700000094009000000
Friday, January 1, 202138751000000103077000000
Saturday, January 1, 202240640000000113840000000
Sunday, January 1, 202333903000000202972000000
Monday, January 1, 20240163607000000
Loading chart...

Data in motion

A Tale of Two Giants: AbbVie Inc. vs Dr. Reddy's Laboratories Limited

In the ever-evolving pharmaceutical industry, the battle for market dominance is fierce. Over the past decade, AbbVie Inc. and Dr. Reddy's Laboratories Limited have showcased contrasting trajectories in their gross profit margins. From 2014 to 2023, AbbVie Inc. saw a steady rise, peaking in 2022 with a 162% increase from its 2014 figures. However, 2023 marked a decline, with profits dropping by 17% from the previous year. In contrast, Dr. Reddy's Laboratories Limited demonstrated a robust growth pattern, with a staggering 168% increase in gross profit from 2014 to 2023. Notably, 2023 was a landmark year for Dr. Reddy's, with profits soaring to unprecedented heights, nearly doubling since 2021. This data underscores the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions can significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025